Australia legalized medical cannabis nationally in 2016, and since then patient numbers have grown from a handful to hundreds of thousands through a prescriber-and-approval system, making it one of the world’s fastest-growing medical markets — even as recreational use remains illegal nationally, with the Australian Capital Territory the notable exception.
Medical legalization in 2016
Australia amended federal law in 2016 to allow the cultivation of cannabis for medicinal and scientific purposes and to permit patient access through regulated pathways. The Therapeutic Goods Administration (TGA) oversees approvals, and most products are accessed through the Special Access Scheme or via authorized prescribers rather than as standard registered medicines.
How patients actually get access
Because few cannabis products are fully registered medicines, most patients receive them through the Authorised Prescriber scheme or Special Access Scheme B, in which doctors apply to prescribe unregistered products. This pathway was initially slow and bureaucratic but was progressively streamlined, and a wave of dedicated cannabis clinics and telehealth services made access far easier by the 2020s.
Explosive growth in numbers
Patient numbers climbed dramatically, from negligible in 2016 to hundreds of thousands of approvals by the mid-2020s. The most commonly prescribed indications include chronic pain, anxiety and sleep disorders, and the market’s rapid expansion has drawn both investment and scrutiny from regulators concerned about prescribing standards.
Regulatory pushback on quality
The rapid growth prompted the TGA and medical boards to tighten oversight, scrutinizing high-volume prescribing, telehealth models and advertising. Regulators have emphasized that medical cannabis is a therapeutic product requiring genuine clinical assessment, not a backdoor to recreational access, and some clinics faced review over their practices.
The ACT’s decriminalization experiment
The Australian Capital Territory, home to Canberra, went further than the rest of the country by decriminalizing personal possession and cultivation of small amounts for adults, effective 2020. This created a legal tension with federal law, under which cannabis remains illegal, but in practice the territory chose not to prosecute personal use — a distinctly Australian federal-state split.
Recreational legalization stays off the table nationally
Despite the medical boom and the ACT experiment, national recreational legalization has not advanced. Proposals and party platforms supporting legalization exist, and some states have expanded diversion and cautioning schemes, but the major parties have not embraced a nationwide regulated recreational market.
Driving laws remain a flashpoint
One of the sharpest debates concerns driving. Australia’s roadside drug testing detects the presence of THC rather than impairment, meaning medical patients can test positive and face penalties days after use even when not impaired. Advocates argue this unfairly criminalizes lawful patients, and several jurisdictions have debated reform.
A growing domestic industry
Australia licensed domestic cultivation and manufacturing, and a local cannabis industry developed alongside imports, with companies growing, processing and exporting products. The country positioned itself as a medical cannabis producer for both domestic use and export to markets such as Europe.
How Australia compares globally
Australia’s model resembles other medical-first countries: broad medical access through a regulated system, cautious politics on recreational use, and ongoing debate. It is more permissive than most of Asia but has not gone as far as Canada or several US states on recreational legalization.
The outlook
The likely trajectory is continued medical-market maturation, tighter prescribing standards, and pressure to reform driving laws for patients. Whether Australia moves toward recreational legalization will depend on state experiments like the ACT’s and shifting public opinion, but for now the story is overwhelmingly a medical one.
Legalization status by the numbers
- Australia: Medical cannabis legal nationally since 2016; hundreds of thousands of patient approvals; recreational illegal except ACT decriminalization
- New Zealand: Medical cannabis legal; 2020 recreational referendum narrowly rejected
- Thailand: Decriminalized cannabis in 2022; policy since tightened toward medical use
- Japan: Strict prohibition; limited medical CBD framework
- South Korea: Medical cannabis permitted in limited forms; recreational strictly banned
The telehealth revolution in access
Much of Australia’s patient surge was driven by telehealth cannabis clinics that made consultations fast and convenient, connecting patients with authorized prescribers remotely. This model democratized access far beyond what the original 2016 framework envisioned, but it also concentrated prescribing among a small number of high-volume clinics, prompting regulators to scrutinize whether clinical standards were being maintained. The tension between improving patient access and preventing a de facto recreational pipeline has become central to how Australia manages its fast-growing market.
What legalization advocates want next
Reform campaigners and some minor parties continue to push for a regulated recreational market, pointing to tax revenue, reduced policing costs and the ACT precedent. They also press for fairer driving laws that distinguish presence of THC from actual impairment, arguing the current regime unfairly penalizes lawful medical patients. While the major parties remain cautious, shifting public attitudes and the visible success of the medical system keep the recreational debate alive, and state-level experiments may again lead where the federal government has been reluctant to follow.
A model of medical-first legalization
Australia has become a leading example of medical-first cannabis policy, in which broad patient access is established and normalized well before any recreational reform is seriously considered. This sequencing built public familiarity, clinical experience and a domestic industry, arguably laying groundwork that could support future recreational debate. Whether Australia ultimately follows Canada toward a regulated recreational market or remains a medical-only country with limited territorial exceptions will depend on evolving public opinion, the outcomes of the ACT’s decriminalization, and whether reform of contentious issues like roadside drug testing builds momentum for broader change.
Exports and Australia’s global role
Beyond serving domestic patients, Australia licensed cultivation and manufacturing partly with an eye on export markets, aiming to supply regulated medical systems in Europe and Asia that depend on imported product. Australian producers compete on quality and regulatory rigor rather than low cost, positioning the country as a trusted supplier in an increasingly crowded global market. This export ambition, combined with the vast domestic patient base, has attracted significant investment and consolidation in the sector. How Australia balances its role as both a large consumer market and an aspiring exporter will shape the industry’s next phase, especially as more countries build their own domestic cultivation capacity.
Related coverage on Weedly
- How Countries Tax Legal Cannabis
- Cannabis In The Uk Medical Recreational
- Inside Germanys Cannabis Clubs Anbauvereinigungen
- Germany Ban Cannabis At Oktoberfest Beer Gardens
- Cannabis In Greece Medical Cultivation


